de Koning HJ - Search Results

1

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Draisma G, et al. Among authors: de koning hj. J Natl Cancer Inst. 2003 Jun 18;95(12):868-78. doi: 10.1093/jnci/95.12.868. J Natl Cancer Inst. 2003. PMID: 12813170 Free article. Clinical Trial.

2

Extra incidence caused by mammographic screening.

Boer R, Warmerdam P, de Koning H, van Oortmarssen G. Boer R, et al. Lancet. 1994 Apr 16;343(8903):979. doi: 10.1016/s0140-6736(94)90105-8. Lancet. 1994. PMID: 7909035 No abstract available.

3

Cost-effectiveness of mammographic screening in Australia.

Carter R, Glasziou P, van Oortmarssen G, de Koning H, Stevenson C, Salkeld G, Boer R. Carter R, et al. Aust J Public Health. 1993 Mar;17(1):42-50. doi: 10.1111/j.1753-6405.1993.tb00103.x. Aust J Public Health. 1993. PMID: 8357894

4

Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study.

Boer R, de Koning H, Threlfall A, Warmerdam P, Street A, Friedman E, Woodman C. Boer R, et al. BMJ. 1998 Aug 8;317(7155):376-9. doi: 10.1136/bmj.317.7155.376. BMJ. 1998. PMID: 9694752 Free PMC article.

5

Reduction in breast cancer mortality due to the introduction of mass screening in The Netherlands: comparison with the United Kingdom.

van den Akker-van Marle E, de Koning H, Boer R, van der Maas P. van den Akker-van Marle E, et al. J Med Screen. 1999;6(1):30-4. doi: 10.1136/jms.6.1.30. J Med Screen. 1999. PMID: 10321368

6

Stage distribution at first and repeat examinations in breast cancer screening.

Boer R, de Koning H, van Oortmarssen G, Warmerdam P, van der Maas P. Boer R, et al. J Med Screen. 1999;6(3):132-8. doi: 10.1136/jms.6.3.132. J Med Screen. 1999. PMID: 10572843

7

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schröder FH; European Randomized Screening for Prostate Cancer (ERSPC) Trial; International Prostate Cancer Screening Trials Evaluation Group. de Koning HJ, et al. Int J Cancer. 2002 Jan 10;97(2):237-44. doi: 10.1002/ijc.1588. Int J Cancer. 2002. PMID: 11774270 Clinical Trial.

8

Should we start population screening for prostate cancer? Randomised trials are still needed.

Auvinen A, Alexander FE, de Koning HJ, Miller AB. Auvinen A, et al. Among authors: de koning hj. Int J Cancer. 2002 Jan 20;97(3):377-8. doi: 10.1002/ijc.1621. Int J Cancer. 2002. PMID: 11774292 No abstract available.

9

Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial.

de Koning HJ, Liem MK, Baan CA, Boer R, Schröder FH, Alexander FE; ERSPC. de Koning HJ, et al. Int J Cancer. 2002 Mar 10;98(2):268-73. doi: 10.1002/ijc.10188. Int J Cancer. 2002. PMID: 11857418 Clinical Trial.

10

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, de Koning HJ. Otto SJ, et al. Among authors: de koning hj. Int J Cancer. 2003 Jun 20;105(3):394-9. doi: 10.1002/ijc.11074. Int J Cancer. 2003. PMID: 12704675 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

494 results

Search Page

Filters